Endomag offers breast cancer technology free to NHS
Cambridge cancer care technology specialist Endomag is offering free support to NHS staff treating patients with breast cancer.
The UK business has partnered with German company Sysmex Europe by donating free Magtrace® lymphatic tracer vials to UK hospitals to help continue essential breast cancer treatment during the COVID-19 outbreak.
Eric Mayes, CEO of Endomag and Keith Howes, MD and head of UK Business at Sysmex Europe, issued a joint statement.
It read: “In these unprecedented times, we'd like to offer our support to the NHS by donating free Magtrace®lymphatic tracer vials to help surgeons in the UK continue to carry out essential breast cancer treatments.
“Following recent updated guidelines from the UK’s Association of Breast Surgery, many breast cancer surgeries will be facing a number of changes up and down the country.
“In recent days, we have been contacted by a number of consultant breast surgeons who are moving their breast services to smaller day-case units, in order to free up space in large hospitals.
“We know that for essential breast cancer surgery this presents challenges, mainly that smaller units may not have regular access to nuclear medicine for sentinel lymph node biopsies and may not want to risk potential adverse reactions from using blue dyes.
“With this in mind we want to offer a helping hand, to ensure patients are receiving the treatment they need.
“In collaboration with our UK partners, Sysmex, we want to help all 50+ hospitals in the UK that currently have a Sentimag® system, who may not have adopted the Magtrace® lymphatic tracer.
“We would like to donate free vials of Magtrace® lymphatic tracer to each of these hospitals, as well as offering guidance and advice to any site that wishes to receive this.”
So how can the Magtrace® lymphatic tracer help hospitals?
- Inject hours or days ahead of the surgery – either at the pre-op visit or on the operating table, minimising the number of visits to hospital
- No nuclear medicine – it does not require a nuclear department to store vials
- No timeout – should the case need to be re-scheduled
- No known risk of anaphylaxis – no instances have been recorded in over 40,000 cases to date
- Non-inferior – the Magtrace® lymphatic tracer has been shown to be non-inferior to the alternative treatment of Tc99 and blue dye in numerous clinical trials involving over 3,000 patients
Providing online support
To receive your free Magtrace® lymphatic tracer vials and support for using them, email supportnhs [at] endomag.com
The partners are making this donation available to all UK hospitals already in possession of a Sentimag® system that are not currently using the Magtrace® lymphatic tracer.
Free vials will be available for a limited time to support during the ongoing COVID-19 pandemic. Availability, or the potential for additional vials, will be reviewed on a regular basis.